Pegcrisantaspase

DB16281InvestigationalProtein Based Therapies

Pegcrisantaspase is under investigation in clinical trial NCT02257684 (A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia... Following Hypersensitivity to Pegaspargase (Oncaspar)).

Mechanism: Pharmacologically active on L-asparagine
Curator reviewed
Also known as: Asparec · mPEG-R-Crisantaspase · Pegylated dickeya chrysanthemi l-asparaginase · Pegylated erwinia chrysanthemi l-asparaginase · POLYETHYLENE-GLYCOL-ERWINIA-CHRISANTHEMI-L-ASPARAGINASE
Code names: JZP-416

Resolves to

Compound

UNIIY8KTZ6Y35UCAS1448590-54-2

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Pegcrisantaspase, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account